Amarin Corporation plc is a pharmaceutical company specializing in the development and commercialization of therapeutics aimed at improving cardiovascular health and reducing cardiovascular risk. The company’s primary focus lies in the prescription drug market, where it has established a leading position with its flagship product, VASCEPA (icosapent ethyl). VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA), a purified omega-3 fatty acid, designed to address elevated triglyceride levels and residual cardiovascular risk in high-risk patients. Amarin operates in a highly regulated industry, navigating complex approval processes, intellectual property challenges, and global commercialization strategies to deliver its therapies to patients and healthcare providers.

Amarin generates revenue primarily through the sale of VASCEPA, which is marketed under the brand names VASCEPA in the United States and VAZKEPA in Europe and other international markets. The company supplies its product to a network of distributors, including major wholesalers, regional wholesalers, and retail and mail-order pharmacies, which then resell the drug to patients. Revenue is also derived from partnerships with commercial collaborators in various regions, where Amarin licenses the rights to develop, market, and distribute VASCEPA in exchange for upfront payments, milestone payments, and royalties. These partnerships extend the drug’s reach into markets such as Canada, China, the Middle East, and Southeast Asia, where local partners handle regulatory approvals, pricing negotiations, and commercialization.

Amarin holds a distinctive position within the cardiovascular pharmaceutical industry, driven by the clinical differentiation of VASCEPA. The drug is the first and only omega-3 therapy approved by the U. S. Food and Drug Administration (FDA) to reduce cardiovascular risk in high-risk patients already receiving statin therapy. This approval was based on the landmark REDUCE-IT trial, which demonstrated a 25% relative risk reduction in major adverse cardiovascular events, a result that has been recognized by over 70 global medical societies in their clinical guidelines. Amarin’s competitive advantage stems from VASCEPA’s unique composition—containing only EPA without docosahexaenoic acid (DHA)—which avoids the LDL-cholesterol-raising effects observed in other omega-3 formulations. Despite facing generic competition in the U. S. for its initial hypertriglyceridemia indication, Amarin maintains exclusivity for its cardiovascular risk reduction indication through patents and regulatory protections extending into the 2030s. Key competitors include generic manufacturers of icosapent ethyl, such as Hikma Pharmaceuticals and Dr. Reddy’s Laboratories, as well as other triglyceride-lowering therapies like Lovaza and fibrates, though none offer the same cardiovascular risk reduction benefits as VASCEPA.

Amarin’s customer base consists primarily of healthcare providers, including cardiologists, endocrinologists, and primary care physicians, who prescribe VASCEPA to high-risk patients with elevated triglycerides. In the U. S., the drug is distributed through major wholesalers such as AmerisourceBergen, Cardinal Health, and McKesson, as well as regional and retail pharmacy chains. Internationally, Amarin collaborates with commercial partners to reach patients in specific markets, including Recordati in Europe, HLS Therapeutics in Canada, CSL Seqirus in Australia and New Zealand, and Eddingpharm in China. These partners manage local distribution, reimbursement negotiations, and physician engagement, ensuring VASCEPA’s availability to patients across diverse healthcare systems. The company’s focus on high-risk cardiovascular patients positions it within a niche but growing segment of the pharmaceutical market, where demand for effective residual risk reduction therapies continues to expand.